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FOXA1 is a pioneer factor that binds to enhancer
regions that are enriched inH3K4mono- anddimethy-
lation (H3K4me1 and H3K4me2). We performed a
FOXA1 rapid immunoprecipitation mass spectrom-
etry of endogenous proteins (RIME) screen in ERa-
positive MCF-7 breast cancer cells and found his-
tone-lysine N-methyltransferase (MLL3) as the top
FOXA1-interacting protein. MLL3 is typically thought
to induce H3K4me3 at promoter regions, but re-
cent findings suggest it may contribute to H3K4me1
deposition. We performed MLL3 chromatin immuno-
precipitation sequencing (ChIP-seq) in breast cancer
cells, and MLL3 was shown to occupy regions
marked by FOXA1 occupancy and H3K4me1 and
H3K4me2. MLL3 binding was dependent on FOXA1,
indicating that FOXA1 recruits MLL3 to chromatin.
MLL3 silencing decreased H3K4me1 at enhancer ele-
ments but had no appreciable impact on H3K4me3
at enhancer elements. We propose a mechanism
whereby the pioneer factor FOXA1 recruits the chro-
matin modifier MLL3 to facilitate the deposition of
H3K4me1 histone marks, subsequently demarcating
active enhancer elements.INTRODUCTION
FOXA1 (Forkhead box protein A1) is a pioneer factor (Jozwik and
Carroll, 2012) that binds to condensed chromatin and allows
subsequent binding of other transcription factors. FOXA1 con-
tributes to chromatin opening to facilitate binding of estrogen re-
ceptor a (ER) in breast cancer (Carroll et al., 2005) and androgen
receptor (AR) in prostate and breast cancer cells (Robinson et al.,
2011; Sahu et al., 2011; Yang and Yu, 2015). ER is a driver of cell
proliferation and tumor growth, and ER-positive breast cancer
accounts for over 70% of all breast cancers (Curtis et al.,
2012). Recent evidence has shown that FOXA1 is essential for
almost all ER binding events in breast cancer (Hurtado et al.,
2011) and for ER functionality, yet our understanding of FOXA1Cell Rep
This is an open access article undactivity and the events involved in determining FOXA1-chromatin
interactions is limited.
FOXA1 binding occurs at enhancer regions enriched in histone
3 lysine 4 mono- and dimethylation (H3K4me1/me2) (Lupien
et al., 2008). While it has been reported that FOXA1 binding re-
quires H3K4me1/me2 marks (Lupien et al., 2008), more recent
findings showed that exogenous expression of FOXA1 in the
FOXA1-negative MDA-MB-231 cell line results in the acquisition
of H3K4me1/me2 at FOXA1-bound sites (Se´randour et al., 2011),
suggesting that FOXA1 may actually contribute to deposition of
the H3K4me1 and H3K4me2 marks rather than associate with
enhancers that are demarcated by the presence of these marks.
Clearly, the order of these events is not resolved, yet FOXA1
binding and the H3K4me1/me2 signal result in a functional
enhancer element that can recruit additional factors (such as
ER) to drive expression of genes, including those involved in
cell-cycle progression.
Unlike H3K4me1 and H3K4me2, which are typically found at
enhancer elements, H3K4me3 is typically observed at pro-
moter regions, and several investigations have associated
the histone-lysine N-methyltransferase enzyme MLL3 with
the deposition of H3K4me3 marks at promoters (Ardehali
et al., 2011; Vermeulen and Timmers, 2010). More recently,
the MLL3/MLL4 complex has been implicated in the regulation
of H3K4me1 in mice (Herz et al., 2012). Importantly MLL3 is
mutated in a number of solid cancers, including 8%–11% of
breast cancers (Ellis et al., 2012; Wang et al., 2011), although
a role for MLL3 in breast cancer and the functional conse-
quences of these mutational events are not known. Silencing
of MLL3 (and the related protein MLL2) has been shown to
decrease the estrogen-mediated activation of HOXC6 in
human placental choriocarcinoma (JAR cell line), and knock-
down of either ERa or ERb abolished estrogen-dependent
recruitment of MLL2 and MLL3 onto the HOXC6 promoter in
the JAR cell line (Ansari et al., 2011).
We sought to discover proteins that interact with FOXA1 in
ER-positive (ER+) breast cancer cells by performing FOXA1
RIME (rapid immunoprecipitation mass spectrometry of endo-
genous proteins), an unbiased proteomic method that permits
discovery of protein networks. This revealed a role for MLL3
as a critical chromatin regulatory protein at enhancer elements
and as a factor that contributes to H3K4me1 deposition at
these enhancers.orts 17, 2715–2723, December 6, 2016 ª 2017 The Authors. 2715
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Purification of FOXA1-Associated
Proteins Using RIME and Mapping of MLL3
Binding Genome-wide
(A) The FOXA1 interactome was discovered by
performing RIME in MCF-7 breast cancer cells. The
data are represented as a Wordcloud, where the
size of protein names represent the strength and
confidence of the interactions based on theMascot
score. MLL3 was identified as one of the strongest
and most reproducible FOXA1-interacting proteins.
(B) Peptide coverage, number of unique peptides
identified, and Mascot score of MLL3 and FOXA1
following FOXA1 purification.
(C) Hypothesized mechanism of FOXA1 and MLL3
function. Our finding that MLL3 and FOXA1 physi-
cally interact inbreast cancer cells implies that FOXA1
could recruit the enzyme that can add methyl groups
to histone 3 lysine 4. FOXA1-bound enhancers are
demarcated by H3K4me1 and H3K4me2.
(D) MLL3 ChIP-seq was conducted and the
genomic distribution of MLL3 peaks is shown
relative to the whole genome (the expected control
values). Regions bound by MLL3 occurred mostly
at enhancers rather than promoters.
(E) De novo motif analysis of MLL3 binding sites.
Motif analysis revealed an enrichment in Forkhead
motif, the canonical motif bound by FOXA1, and
motifs for the transcription factor grainyhead-like 2
protein (GRHL2).RESULTS
RIME Analysis of FOXA1-Associated Proteins Reveals
Interactions with MLL3 in Breast Cancer Cells
We performed RIME (Mohammed et al., 2013) of FOXA1 in
MCF-7 breast cancer cells to identify endogenous FOXA1 inter-
actors. Asynchronous MCF-7 cells were grown in full media, and
five replicates of FOXA1 RIME were conducted. MLL3 was iden-
tified as one of the strongest and most reproducible interactors
(Figure 1A), and the peptide coverage, number of unique pep-
tides identified, and Mascot score of MLL3 and FOXA1 are
shown in Figure 1B. A full list of FOXA1-interacting proteins is
provided in Table S1. We hypothesized that this interaction
may be functional, as the pioneer factor FOXA1 binds at
enhancer regions enriched in H3K4me1/me2 histone marks
and FOXA1 has been shown to contribute to the acquisition of
the H3K4me1/me2 mark (Se´randour et al., 2011). In addition,
loss of MLL3 has been previously shown to correlate with
reduced H3K4me1 at specific regions within the genome in
mice (Herz et al., 2012). Our findings thatMLL3 and FOXA1 phys-
ically interact in breast cancer cells implies that FOXA1 may be
able to directly recruit the enzyme that can add methyl groups
to the H3K4 residue (Figure 1C).
Global Mapping of MLL3 Binding Sites Shows
Enrichment at Enhancers
Due to the size of MLL3 (540 kDa) and the fact that FOXA1 is
the same size at the antibody heavy chain, we were unable to
conduct co-immunoprecipitation (co-IP) validation experiments
on the MLL3-FOXA1 interaction. However, we explored this pu-
tative interaction in several ways. We reversed the pull-down,2716 Cell Reports 17, 2715–2723, December 6, 2016purified MLL3, and could discover FOXA1 as an interacting pro-
tein by RIME (data not shown). In addition, we assessed the
global interplay between MLL3 and FOXA1 binding events by
performing MLL3 and FOXA1 chromatin immunoprecipitation
sequencing (ChIP-seq). Asynchronous MCF-7 cells were grown
and triplicate ChIP-seq experiments were conducted. MLL3
ChIP-seq was conducted using a custom antibody that we vali-
dated by RIME and could show to be specific to MLL3 (Fig-
ure S1A). Data from all the replicates were pooled, and peaks
were called using model based analysis for ChIP-seq (MACS)
(Zhang et al., 2008), resulting in a total of 10,772 MLL3 binding
events in MCF-7 cells. MLL3 has been previously implicated as
an enzyme that contributes to H3K4me3 deposition at promoter
regions (Ananthanarayanan et al., 2011), but our ChIP-seq data
showed that MLL3 binding was mostly distributed at enhancer
elements and intergenic regions (Figure 1D) with a smaller frac-
tion distributed at promoters, similar to what has been observed
for ER and FOXA1 (Carroll et al., 2005; Hurtado et al., 2011).
Analysis of enrichedDNAmotifs within theMLL3 binding sites re-
vealed an enrichment of Forkhead motifs, the canonical motif
bound by FOXA1 (MEME e-value = 8.9e-512). In addition, motifs
for the transcription factor grainyhead-like 2 protein (GRHL2)
were identified (Figure 1E) (MEME e-value = 2.6e-116), although
there is limited information linking GRHL2 and ER/FOXA1
signaling.
MLL3 Binding Is Dependent on FOXA1 and Is Required
for ER Activity
ChIP-seq of FOXA1 and H3K4me1/me3were performed in asyn-
chronous MCF-7 cells in triplicate, and peaks were called using
MACS, revealing 23,375 FOXA1 peaks, 26,584 H3K4me1, and
13,478 H3K4me3 peaks. The binding of FOXA1 and H3K4me1/
me3 was overlapped with the MLL3 binding sites. The majority
(55.8%) of MLL3 binding events were co-bound by FOXA1 (Fig-
ure 2A), and since H3K4me1 is associated with FOXA1, it was
not unexpected that MLL3/FOXA1-co-bound regions were also
typically marked by H3K4me1 (Figure 2A). A small percentage
(9.1%) of MLL3/FOXA1 co-bound regions were also marked by
histone 3 lysine 4 trimethylation (H3K4me3) (Figure S2B). An
example of a MLL3 and FOXA1 co-bound region, marked by
both H3K4me1 and H3K4me3, is shown in Figure 2B. Heatmap
visualization of the FOXA1 binding and H3K4me1/me3 signal at
the MLL3 binding events is shown in Figure 2C, indicating that a
substantial degree of the MLL3 and FOXA1 co-bound regions
also possess H3K4me1 signal.
Given that MLL3 was the top FOXA1-interacting protein (Fig-
ure 1A), that MLL3 binding sites were enriched for Forkhead
motifs, and that 55.8% of MLL3 binding events we also FOXA1
binding sites, we hypothesized that MLL3 was recruited to
the chromatin by FOXA1. To assess this, MCF-7 cells were
transfected with small interfering RNA (siRNA) to control (siCon-
trol) or siRNA to FOXA1, and effective FOXA1 silencing was
confirmed. Following FOXA1 silencing, MLL3 ChIP-seq was
conducted in triplicate independent biological replicates. MLL3
peaks were called in siControl or siFOXA1-transfected condi-
tions. This resulted in a global decrease in MLL3 binding
when FOXA1 was depleted (Figure 2D). The decreased MLL3
binding following silencing of FOXA1 was not due to a decrease
in MLL3 expression, since MLL3 mRNA levels increased
following FOXA1 silencing (Figure S2A). Six MLL3 binding
sites were assessed using ChIP-qPCR, validating the depen-
dence on FOXA1 for MLL3 binding to chromatin (Figure S2C).
Given the importance of FOXA1 in recruiting MLL3 to the
chromatin, we speculated that FOXA1 promotes H3K4me1
to activate enhancers via MLL3. Consistently, knockdown of
FOXA1 decreased H3K4me1 as well as H3K27ac on ER-depen-
dent enhancers (as shown in Figure S2D), which are absent for
H3K27me3 (Figures 2E and S2E). Importantly, MLL3 knockdown
showed a significant decrease in ER-induced gene transcription
and proliferation (Figures 2F, 2G, and S2G), which highlights the
importance of MLL3 in ER-activated transcription.
Chromatin Properties at MLL3 Binding Events
As previously observed (Figure 1E), GRHL2 (grainyhead-like 2
protein) motifs were enriched within MLL3 binding events.
GRHL2 was also found to be a FOXA1 interacting protein from
the RIME experiments (Figure 1A), suggesting that the enrich-
ment of GRHL2 motifs might represent a functional interaction
between FOXA1 andGRHL2. The role of GRHL2 in breast cancer
is currently unclear, with both pro-metastatic and anti-metasta-
tic roles (Werner et al., 2013; Xiang et al., 2012). We performed
GRHL2 ChIP-seq in MCF-7 cells in triplicate, and GRHL2 peaks
were called using MACS, revealing 30,143 GRHL2 binding sites.
GRHL2 binding was overlaid with MLL3 and FOXA1 binding,
revealing 5,585 regions that were occupied by all three factors
with significant overlap with ERa (Figures 3A and S3). An
example of a co-occupied site is shown in Figure 3B. In total,
91.5% of MLL3 binding sites were co-occupied by FOXA1
and/or GRHL2. To gain insight into the mechanisms involved inthe different cis-regulatory elements, we explored the seven
different categories of binding by investigating regions bound
by a single factor (FOXA1 only, MLL3 only, or GRHL2 only),
two factors (FOXA1 and MLL3, MLL3 and GRHL2, or GRHL2
and FOXA1), or all three factors and used them for further ana-
lyses. Only 1.6%of theMLL3 binding regions were not co-bound
by FOXA1, GRHL2, or both, suggesting that MLL3 cannot asso-
ciate with chromatin without one of the associated transcription
factors, and the MLL3-only binding regions were subsequently
eliminated from further analyses.
In control conditions, MLL3 binding wasmost enriched at sites
co-occupied by FOXA1, GRHL2, or both proteins together, sug-
gesting that optimal MLL3-chromatin occupancy involves at
least one of the additional transcription factors (Figure 3C).
Following silencing of FOXA1, MLL3 binding was substantially
reduced at two categories: the first was the regions bound
by all three proteins, and the second was the FOXA1 and
MLL3 (but not GRHL2) regions. Interestingly, MLL3 binding
signal at MLL3 and GRHL2 (but not FOXA1) occupied cis-regu-
latory elements were moderately affected by FOXA1 silencing,
suggesting multiple modes of MLL3-chromatin occupancy (Fig-
ure 3C). This suggests that upon FOXA1 silencing, MLL3 binding
sites were lost at any region where FOXA1 co-binds, even
if GRHL2 is also present, but MLL3 binding is moderately
affected at regions where GRHL2 is the sole protein associated
with MLL3.
When the different MLL3 binding regions were integrated with
the H3K4me1/me3 data, the most enriched regions were those
where MLL3, FOXA1, and GRHL2 were co-bound and those
where MLL3 and FOXA1 were co-bound, although any region
occupied by MLL3 had an increased H3K4me1 signal relative
to regions occupied by FOXA1 or GRHL2, but not MLL3 (Fig-
ure 3D). These findings confirm that the presence of MLL3
correlates with increased H3K4me1.
Since FOXA1 contributes to the establishment of enhancer
elements that are subsequently used by transcription factors
such as ER in these breast cancer cells, we integrated the
MLL3, FOXA1, and GRHL2 ChIP-seq data with ER binding infor-
mation. As expected (Figures S2D), the regions bound by FOXA1
and MLL3 are commonly co-occupied by ER, in support of their
role in establishing ER enhancer elements.
H3K4me1 at Enhancer Elements Is Dependent on
MLL3
Given thatMLL3 bindingwas associatedwith regions enriched in
H3K4me1 marks and MLL3 is a methyltransferase, we hypothe-
sized that MLL3 contributes to the presence of this methyl mark
at enhancer elements. To assess this, MCF-7 cells were trans-
fected with siControl or siMLL3 and triplicate H3K4me1 and
H3K4me3 ChIP-seq experiments were conducted, and peaks
were called using MACS. When MLL3 was silenced, deposition
of H3K4me1 was substantially decreased at both enhancer ele-
ments and promoters (Figure 4A). We specifically assessed the
changes in H3K4me1 at regions bound by both FOXA1 and
MLL3, resulting in the identification of 776 FOXA1/MLL3-bound
enhancers that had decreased H3K4me1 following MLL3
silencing (Figure 4B). There was no decrease in H3K4me3 at
either the enhancer elements or the promoter regions whenCell Reports 17, 2715–2723, December 6, 2016 2717
Figure 2. Co-binding of MLL3, FOXA1, and H3K4me1/me3 and Mechanism of MLL3 Recruitment
(A) Overlap of MLL3, FOXA1, and H3K4me1 binding revealed by ChIP-seq. MLL3 binding sites were co-bound by FOXA1 and the histone marks. The numbers of
peaks within each category are shown on the diagram.
(B) An example of an MLL3, FOXA1, and H3K4me1/me3 co-bound region at the GREB1 enhancer.
(C) Heatmap of MLL3-FOXA1 co-bound regions showing binding signal intensity for FOXA1, MLL3, H3K4me1, and H3K4me3. Binding is ranked from the
strongest to the weakest binding sites.
(D) Signal intensity plot representing changes in MLL3 ChIP-seq signal in siControl versus siFOXA1-transfected conditions. Differentially bound sites needed to
be detected in at least two replicates to be included.
(E) ChIP-qPCR analyses of H3K4me1 after knockdown of FOXA1 on ER-bound enhancers of TFF1 and PGR. n = 3; mean ± SD is shown as the of percentage of
input. *p% 0.05.
(F) qRT-PCR of estrogen-induced genes TFF1 and PGR with or without knockdown of MLL3 after 3 days of charcoal-stripped serum ±10 nM estrogen (E2)
treatment. n = 3; mean ± SD is shown in average relative mRNA levels compared to the vehicle (Veh) condition. *p < 0.05, **p < 0.01, ***p < 0.001.
(G) Estrogen-induced proliferation assays with or without knockdown of MLL3 after 3 days of charcoal-stripped serum ±10 nM estrogen treatment for 8 days.
n = 4; mean ± SEM of percentage of confluency is shown.
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Figure 3. Functional Distinction between
Regions Bound by FOXA1, GRHL2, and
MLL3
(A) Venn diagram showing the overlap of MLL3,
FOXA1, and GRHL2 binding regions, identifying
the different categories of binding events. For
subsequent analyses, we assessed the number of
regions co-bound by one factor (FOXA1 only,
MLL3 only, or GRHL2 only), two factors (FOXA1
and MLL3, MLL3 and GRHL2, or GRHL2 and
FOXA1), and all three factors.
(B) An example of an MLL3, FOXA1, ERa, and
GRHL2 co-bound region.
(C) Average MLL3 binding signal in siControl and
siFOXA1 conditions at the different binding cate-
gories. Following FOXA1 silencing, MLL3 binding
intensity was reduced at regions occupied by
MLL3, FOXA1, and GRHL2, regions occupied by
MLL3 and FOXA1, and to a lesser extent at regions
occupied by MLL3 and GRHL2.
(D) H3K4me1/me3 distribution at the different
binding regions. The most enriched H3K4me1 re-
gions were those where MLL3 was recruited.MLL3 was silenced and a modest gain of signal at both pro-
moters and enhancer elements were observed (Figure 4C). We
assessed the 776 enhancer elements with decreased
H3K4me1 following MLL3 silencing for enriched pathways.
Genomic Regions Enrichment of Annotations Tool (GREAT) re-
vealed a number of enriched pathways, most of which were
associated with transcriptional regulation (Figure 4D). Given
the observation that regions bound byMLL3 possess the highest
H3K4me1 signal (Figure 3D) and that H3K4me1 was depleted at
enhancers when MLL3 was silenced, we postulate that
H3K4me1 deposition is mediated by MLL3 at enhancer ele-
ments, as determined by FOXA1 and/or GRHL2 recruitment of
MLL3. In support of this, MCF-7 cells were transfected with si-
Control or siFOXA1, and H3K4me1 ChIP-qPCR was conducted
on a select number of loci (the genomic regions and the relative
factor binding is shown in Figure S2H). Following inhibition of
FOXA1, the H3K4me1 signal was diminished at some of the as-
sessed loci (Figures 2E and S2F), and H3K27Ac was alsoCell Repodecreased following FOXA1 inhibition
(Figure S2E), which implies that FOXA1
and MLL3 are required for transcriptional
activity from enhancer elements.
DISCUSSION
We propose a mechanism whereby the
pioneer factor FOXA1 interacts with
chromatin and recruits the methyltrans-
ferase MLL3, facilitating the deposition
of H3K4me1 in breast cancer cells (Fig-
ure 4E). This denotes that an enhancer-
specific pioneer factor FOXA1 can
interact with a chromatin modifier (MLL3)
to facilitate the occurrence of the
H3K4me1 histone mark at regions thatbecome functional enhancer elements. We have described links
among FOXA1, MLL3, and H3K4methylation, revealed by RIME,
an unbiased proteomic technique that showed MLL3 to be a
robust FOXA1-interacting protein in MCF-7 breast cancer cells.
MLL3 has been shown to contribute to H3K4me3 at promoter re-
gions (Ananthanarayanan et al., 2011), but our evidence would
suggest that MLL3 can also contribute to H3K4me1 marks at
enhancer regions and that this is determined by the transcription
factors that recruit MLL3 to the chromatin. Two mechanisms
for MLL3 recruitment to chromatin are revealed by mining of
MLL3 ChIP-seq data. Motifs for Forkhead and GRHL2 trans-
cription factors were identified. Interestingly, MLL3-chromatin
occupancy was shown to occur via FOXA1, GRHL2, or both fac-
tors, and our functional experiments confirm that FOXA1 is
essential for MLL3 binding. GRHL2 has been implicated in
metastasis in breast cancer (Werner et al., 2013; Xiang et al.,
2012), and we hypothesize that its influence on cell migration
and metastatic potential is attributed to its ability to tetherrts 17, 2715–2723, December 6, 2016 2719
Figure 4. Direct Dependency of H3K4me1 on MLL3 at Enhancers
The effect of MLL3 silencing on H3K4me1 and H3K4me3 binding were assessed by ChIP-seq in siControl or siMLL3-transfected cells. Differential H3K4me1 and
H3K4me3 peaks that were altered by silencing of MLL3 were identified.
(A) The average signal intensity of H3K4me1 at enhancer elements or promoters following silencing of MLL3.
(B) Heatmap of differential H3K4me1 regions that occur at FOXA1/MLL3 co-bound regions.
(C) The average signal intensity of H3K4me3 at enhancer elements or promoters following silencing of MLL3.
(D) Enriched pathways within the 776 FOXA1/MLL3 co-bound regions that had a decreased H3K4me1 signal following silencing of MLL3.
(E) Model showing FOXA1 and GRHL2 recruitment of MLL3, which subsequently contributes to monomethylation of H3K4.
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MLL3 at chromatin and mediate enhancer activity. Whether
GRHL2 is involved in ER/FOXA1+ breast cancer or can function
independently of FOXA1 (and ER) is not clear, but GRHL2 is
located on chromosome 8 and is commonly co-amplified with
c-Myc, suggesting that any role for GRHL2 in mediating recruit-
ment of the enzymeMLL3may be substantially altered in tumors
with the commonly occurring chromosome 8 amplification.
The predominant paradigm is that H3K4me1 and H3K4me2
marks are signatures of enhancer regions, whereas H3K4me3 is
enriched at the promoters of coding genes (Calo and Wysocka,
2013; Heintzman et al., 2007, 2009). Our findings would suggest
that the H3K4me1 marks at enhancers are enriched at FOXA1-
bound enhancer elements, because this pioneer factor is able to
recruit the enzyme that contributes to the deposition of this
methylation event at regions co-bound by FOXA1, GRHL2, and
the methyltransferase MLL3. Recently, it has been reported that
MLL3/4 contributes to monomethylation (H3K4me1) of promoter
regions in myoblasts (Cheng et al., 2014). It has also been shown
that Trr, theDrosophila homolog of themammalianMLL3/4COM-
PASS-likecomplexes, can functionasamajorH3K4monomethyl-
transferase on enhancers in vivo (Herz et al., 2012), with amodest
decrease of H3K4me1 in mouse embryonic fibroblasts (MEFs)
fromMLL3 knockout mice (Herz et al., 2012). In our breast cancer
cells,we see apronounceddepletion ofH3K4me1 followingMLL3
silencing. Since MLL3 and the related protein MLL4 function as a
complex, it is possible that bothMLL3 andMLL4 contribute to the
enhancer H3K4methylationmarks, as both proteins needed to be
deleted inMEFs in order to produce the decrease in theH3K4me1
(Herz et al., 2012). However, we did not findMLL4 as a FOXA1-in-
teracting protein, and no FOXA1-MLL4 interactions were
observed, even inMLL3-depletedcells (datanot shown), suggest-
ing a lack of redundancy between MLL3 and MLL4 in our breast
cancer cells. It has also been shown that unlike MLL3, the deple-
tion of MLL4 had no effect on the estrogen-mediated activation of
HOXC6 (Ansari et al., 2011), suggesting thatMLL4 is not function-
ally linkedwithERbiology.Thespecific role forMLL3 inER+breast
cancer is supported by the recent finding that MLL3 was mutated
in 5 out of 46 ER+ breast cancer samples (Ellis et al., 2012), and
although the mutations occur at distinct regions within MLL3, a
common result is putative pertubation in key enzymatic domains
within MLL3. The functional significance of these mutations war-
rants investigation, although the large size of MLL3 (541 kDa)
makes these functional experiments a challenging endeavor.
Taken together, we propose a mechanism by which the
pioneer factor FOXA1 interacts with the chromatin modifier
MLL3 to facilitate monomethylation of H3K4 at enhancer ele-
ments, resulting in the potential for transcription from these
enhancer regions. These findings imply that the transcription
factors that associate with enhancer elements are capable of
actively contributing to the H3K4me1 that occurs at enhancers
rather than requiring H3K4me1 presence for chromatin
occupancy.EXPERIMENTAL PROCEDURES
Cell Lines
MCF-7 cells were obtained from ATCC. MCF-7 cells were grown in DMEM
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mML-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin. All cell lines
were regularly genotyped using STR profiling (Promega GenePrint 10 system).
Cell lines were regularly tested for mycoplasma infection.
Antibodies
The antibodies used for ChIP-seq were anti-FOXA1 (ab5089) from Abcam,
anti-H3K4me1 (ab8895) from Abcam, anti-H3K4me3 (05-1339) from Millipore,
anti-H3K27ac (C15410196) from Diagenode, anti-H3K27me3 (C15410195)
from Diagenode, anti-GRHL2 (HPA004820) from Sigma-Aldrich, and negative
control immunoglobulin G (IgG) anti-rabbit IgG (sc-2027), and anti-goat (sc-
2028) from Santa Cruz Biotechnology. The custom anti-MLL3 antibody was
provided by Prof. Ali Shilatifard (Stowers Institute, Kansas City, MO, and
Northwestern University Feinberg School of Medicine, Chicago, IL).
ChIP-Seq
ChIP was performed as described previously (Schmidt et al., 2009). ChIP-seq
and the input libraries were prepared using the TruSeq ChIP Sample Prep Kit
(Illumina). ChIP-seq of each factor was performed in at least biological tripli-
cates. Reads were mapped to hg19 genome using Gsnap version 2015-09-
29 (Wu and Nacu, 2010). Aligned reads with the mapping quality less than
five were filtered out. The read alignments from three replicates were com-
bined into a single library, and peaks were called with model based analysis
for ChIP-seq 2 (MACS2) version 2.0.10.20131216 (Zhang et al., 2008) using se-
quences from MCF-7 chromatin extracts as a background input control. For
the ChIP samples of histones with mono- and trimethyl modifications, the
broad peaks were called. The peaks yielded with MACS2 q value % 1e-5
were selected for downstream analysis. Meme version 4.9.1 (Bailey et al.,
2009) was used to detect known and discover binding motifs among tag-en-
riched sequences. For visualizing tag density and signal distribution heatmap,
the normalized tumor read coverage in a window of a ±2.5- or 5-kb region
flanking the tag midpoint was generated using a bin size of 1/100 of the win-
dow length. Differential binding analysis (Diffbind) was performed as described
previously (Stark and Brown, 2011).
For ChIP-qPCR, primer sequences used were TFF1 forward, 50-GTGGTT
CACTCCCCTGTGTC-30; TFF1 reverse, 50-GAGGCATGGTACAGGAGAGC-
30; GREB1 forward, 50-CACGTCCCCACCTCACTG-30; GREB1 reverse, 50-TGT
TCAGCTTCGGGACACC, PGR forward, 50-GCTCCAGCTAACTGATGGTCTG-
30; PGR reverse, 50-TGGGCCTAGATTATTGAGTTCAGG-30.
RIME
RIME was performed as previously described (Mohammed et al., 2013).
Proteins were digested using trypsin. Maximum allowed missed cleavage
was 2, the peptide threshold was 95% and the protein false discovery rate
(FDR) was set to 0.5%. Proteins were considered as interactors when at least
2 high-confident peptides were identified and when none of these peptides
were observed in matched IgG control RIME experiments. Additionally,
FOXA1 interactors were filtered using the CRAPome database (http://www.
crapome.org).
Small Interfering RNA Transfections
siRNAs used to silence FOXA1 were obtained from Dharmacon RNAi Technol-
ogies. The sequence of the siRNA that targeted FoxA1 is 50-GAGAGA
AAAAAUCAACAGC-30 and has been previously validated (Hurtado et al.,
2011). Small interfering Smartpool RNAs used to silence MLL3 were obtained
from Dharmacon (L-007039-00-0020 and MQ-004828-02-0002). AllStars
Negative Control siRNA (QIAGEN) and siGenome Non-targeting siRNA
(D-001210-02-05) from Dharmacon were used as a negative controls. Cells
were transfected with siRNA using Lipofectamine 2000 (Invitrogen) and
Lipofectamine RNAiMAX (Thermo Scientific).
Preparation of mRNA
Cells cultured in 15-cm2 dishes were first washed twice with cold PBS, and
RNA was extracted using the RNeasy kit (QIAGEN) per the manufacturer’s
instructions. DNA was degraded by adding 20 U RNase-free DNaseI (Roche
Diagnostics GmbH) for 15 min at room temperature. DNase I treatment was
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Preparation of cDNA
200 ng to 1 mg total RNA was diluted to a final volume of 11 mL using 100 mg
random primers (Promega), 2.5 mM dNTP mix, and nuclease-free water.
This mixture was then incubated at 65C for 5 min. First-strand buffer (Invitro-
gen) and 10 mM 1.4 DTT (Invitrogen) was then added, and this mixture was
incubated at 25C for 10 min to allow primer annealing. The mixture was
then heated at 42C for 1min, and 200 U SuperScript III Reverse Transcriptase
(Invitrogen) was added. The final mixture was then incubated at 42C for an
additional 50 min, and the process was stopped after inactivating the enzyme
at 70C for 15 min. The resulting cDNA was then diluted 1:10 in H2O for sub-
sequent use.
qRT-PCR
qPCR was performed using a Stratagene Mx3005P RealTime machine.
Each qPCR reaction contained Power SYBR green PCR Master Mix (Applied
Biosystems), 250 nM of each primer, 2 mL DNA eluted after chromatin immu-
noprecipitation, and nuclease-free H2O added to a final volume of 20 mL. The
PCR program consisted of first heat-activating the Taq polymerase at 95C
for 10 min. This was then followed by 45 cycles of 15 s at 95C and 30 s at
60C. The fluorescence from each well was analyzed at every cycle. The final
step involved increasing the temperature from 65C to 95C and continu-
ously reading the fluorescence. Reactions were performed in triplicate, and
results were analyzed using the delta-delta Ct method (Livak and Schmitt-
gen, 2001). The enrichment was normalized with control mRNA levels of
ubiquitin C (UBC), and relative mRNA levels were calculated comparing to
vehicle.
For qRT-PCR, primers used were UBC forward, 50-ATTTGGGTCGCGGTTC
TTG-30; UBC reverse, 50-TGCCTTGACATTCTCGATGGT-30; TFF1 forward, 50-
GTGTCACGCCCTCCCAGT-30; TFF1 reverse, 50-GGACCCCACGAACGGTG-
30; PGR forward, 50-CTTAATCAACTAGGCGAGAG-30; PGR reverse, 50-AAG
CTCATCCAAGAATACTG-30; MYC forward, 50-GCCACGTCTCCACACATC
AG-30; MYC reverse, 50-TCTTGGCAGCAGGATAGTCCT-30; GREB1 forward,
50-GCTAACCATGCTGCAAATGA-30; GREB1 reverse, 50-ACACAGTCAGGG
CAAAGGAC-30; MLL3 forward, 50-TGCCTGTTCTCAGTGTGGTC-30; MLL3
reverse, 50-TCACACAGCAGGAGTCTTCC; FOXA1 forward: 50-GGGGGTTT
GTCTGGCATAGC-30; and FOXA1 reverse, 50-GCACTGGGGGAAAGGTTG
TG-30.
Proliferation Assays
Proliferation assays were performed in Incucyte analysis system (FLR 10X
from Essen Bioscience). After reverse transfection with siRNAs, cells were
treated with charcoal stripped serum (kindly provided by Dr. Mohammed
Asim, CRUK, Cambridge, UK) for 3 days and then treated with 10 nM estro-
gen (Sigma), and cell confluence was assessed. Relative confluency was
calculated by comparing it to that of estrogen-treated control siRNA
conditions.
Statistical Methods
To detect significant regions bound with each factor from ChIP-seq data dur-
ing MACS2, the threshold of q value% 1e-5 was used. FDR% 0.5%was used
for RIME data analysis. The e-value was used to detect significant motifs from
MEME analysis. For qPCR analyses, p values were calculated using ANOVA or
Student’s t test, and values % 0.05 were considered as significant. The bar
graphs were represented as mean ± SD for qPCR and mean ± SEM for prolif-
eration assays. Three to four biological replicates were used throughout the
study.
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